Popular Trials
Vitamin E Derivative
Tocotrienol for End Stage Liver Disease
This trial is to see if a previous trial's results were accurate- that Tocotrienol (TCT) could help end stage liver disease / cirrhosis patients by taking 2 capsules of it (200mg) or placebo twice a day for 3 years.
HMG-CoA Reductase Inhibitor
Statins for Non-alcoholic Steatohepatitis (NASH)
This trial will test whether or not a daily dose of atorvastatin (a type of statin) is effective in treating NASH and hepatic fibrosis, and whether it is safe. The results of this study will help design a larger study on the matter.
Thiazolidinedione
Low-Dose Pioglitazone for NASH
This trial is testing a small daily dose of pioglitazone in patients with type 2 diabetes and a specific liver condition called NASH. The goal is to see if this medication can improve their liver health by helping their bodies manage blood sugar and fat levels better.
Popular Filters
Trials for NAFLD Patients
Glucagon-like peptide-1 (GLP-1) receptor agonist
Efinopegdutide for Nonalcoholic Steatohepatitis (NASH)
This trial is testing a new medicine called efinopegdutide to see if it can help people with a liver disease called non-alcoholic steatohepatitis (NASH). Researchers want to find out if this medicine can reduce the symptoms of NASH without making liver scarring worse. They are also checking how safe the medicine is and how well people can tolerate it.
Behavioural Intervention
Low-Fructose Diet for Fatty Liver Disease in Youth
This trial will compare how two different diets (high vs low in high fructose corn syrup or HFCS) may affect how much fat gets deposited in the liver and whether or not a lower diet in HFCS can help decrease liver damage in adolescents with non-alcoholic fatty liver disease (NAFLD).
Trials for Metabolic Syndrome Patients
Growth Hormone Releasing Hormone Analog
Tesamorelin for Non-alcoholic Fatty Liver Disease
This trial is investigating whether a drug called tesamorelin, which helps the body produce growth hormone, can reduce the amount of fat in the liver and improve liver inflammation in people with obesity and nonalcoholic fatty liver disease.
Behavioural Intervention
Weight Loss for Obesity and Metabolic Syndrome
This trial is investigating how fat is stored in organs, and why this impacts some people's health more than others. The findings could lead to better treatments for diabetes and cardiovascular disease.
Procedure
BI 3006337 for Fatty Liver Disease
This trial is testing a new medicine called BI 3006337 in adults who are overweight or obese and have fatty liver disease. The goal is to find out how much of the medicine they can safely take. Participants receive regular injections and are closely monitored for any health issues.
Caloric Restriction for Insulin Resistance
This trial is investigating if losing a small amount of weight can help people who are at risk for diabetes because of their family history. The study focuses on lean individuals who have trouble using insulin properly. By reducing fat in their muscles and liver, the researchers hope to improve their body's response to insulin and better manage blood sugar levels.
Phase 3 Trials
Glucagon-like peptide-1 receptor agonist
Semaglutide for Non-alcoholic Steatohepatitis
This trial is studying a medication called semaglutide in patients with NASH. Semaglutide is a well-known medication used to treat type 2 diabetes, and participants will either receive semaglutide or a dummy medication, with no way of knowing which they're getting. The study will last for 5 years, during which participants will have to inject themselves weekly and will have 21 clinic visits and 9 phone calls with clinical staff. Some of the clinic visits may last more than one day.
Galectin Inhibitor
Belapectin for NASH Cirrhosis
This trial is testing belapectin, a medication aimed at helping people with a severe liver condition called NASH cirrhosis. The study focuses on patients who have high blood pressure in their liver but no swollen veins in their esophagus. Belapectin works by reducing liver inflammation and scarring, which can improve liver function and reduce health problems.
Thyroid Hormone Receptor Agonist
Resmetirom for Fatty Liver Disease
This trial is testing a medication called MGL-3196 to see if it can help treat patients with NASH and liver fibrosis. The medication works by reducing fat and inflammation in the liver, which can help heal and protect it from further damage.
Thyroid Hormone Receptor Agonist
Resmetirom for Non-alcoholic Fatty Liver Disease
This trial is studying the safety and tolerability of Resmetirom, a pill taken regularly. It involves patients who are already using this medication. Resmetirom helps manage certain health conditions by targeting specific parts of the body and has shown to reduce liver fat in patients with non-alcoholic steatohepatitis (NASH) in previous studies.
Hormone Therapy
Estrogen Therapy for NASH in Postmenopausal Women
This trial will study the effect of the hormone estradiol on non-alcoholic steatohepatitis (NASH) in post-menopausal women. NASH is a growing epidemic in the United States with limited treatment options.
Trials With No Placebo
Behavioural Intervention
Low-Fructose Diet for Fatty Liver Disease in Youth
This trial will compare how two different diets (high vs low in high fructose corn syrup or HFCS) may affect how much fat gets deposited in the liver and whether or not a lower diet in HFCS can help decrease liver damage in adolescents with non-alcoholic fatty liver disease (NAFLD).
Behavioural Intervention
Weight Loss for Obesity and Metabolic Syndrome
This trial is investigating how fat is stored in organs, and why this impacts some people's health more than others. The findings could lead to better treatments for diabetes and cardiovascular disease.
Trials Offering Remuneration
RNAi Therapeutics
ALN-PNP for Healthy Subjects
This trial is testing a new drug called ALN-PNP on healthy people and those with a specific liver condition (NAFLD) and gene variant. The goal is to see if the drug is safe, tolerable, and effective in reducing liver fat. Researchers are also studying how the body processes the drug.
Corticosteroid
Miricorilant for Liver Impairment
This trial tests how the drug miricorilant behaves in people with normal livers and those with moderate liver issues, including some with NASH. It aims to see if liver problems affect how the drug is processed in the body.
View More Related Trials
Frequently Asked Questions
Introduction to fatty liver disease
What are the top hospitals conducting fatty liver disease research?
Fatty liver disease, a condition characterized by the accumulation of fat in the liver, has become a significant health concern worldwide. Fortunately, several top hospitals are leading the way in conducting clinical trials to better understand and effectively treat this condition. In Boston, Massachusetts General Hospital stands out with its six ongoing trials and extensive experience of 24 completed fatty liver disease studies. Since initiating their first trial in 2010, this renowned institution has been deeply committed to unraveling the complexities of this disease.
Moving across the country to Rialto, California, we find another dedicated facility making strides in fatty liver disease research. The Inland Empire Liver Foundation is currently undertaking six active clinical trials while boasting an impressive track record of 28 completed studies since starting their exploration into this field in 2015.
Meanwhile, on the sunny shores of Lakewood Ranch in Florida, the Florida Research Institute is also actively engaged in six ongoing clinical trials focused on fatty liver disease. This relatively new player—having recorded its first trial just five years ago—demonstrates remarkable commitment to advancing our understanding and treatment options for this condition.
Heading further west to Fresno Clinical Research Center located within California's Central Valley region - they too have made valuable contributions through their dedication toward combating fatty liver diseases via engaging themselves into five present-day investigations complemented by twelve previously held experiments since 2015.
Lastly but certainly not least,Duke University Medical Center situated at Durham specializes not only as one among leading academic medical institutions but similarly offers hope for individuals affected by Fatty Liver Disease. With an admirable count of five active clinical tests alongside twenty-seven prior conducted examinations from as early as2005; Duke demonstrates unwavering determination towards unlocking potential solutions against such ailments through extensive research endeavors.The collaborative efforts showcased by these various hospitals signify that groundbreaking progress can be achieved when experts unite forces with shared goals.Through continuous exploration and innovative approaches,future treatments may emerge providing relief and renewed hope for those affected by fatty liver disease.
Which are the best cities for fatty liver disease clinical trials?
When it comes to fatty liver disease clinical trials, several cities emerge as prominent locations for ongoing research. San Antonio, Texas leads the way with 63 active trials investigating treatments like VK2809, AXA1125, and Tirzepatide. Miami, Florida closely follows with 59 trials studying IVA337, Study 1 ALN-HSD Low Dose, Obeticholic Acid, among others. Los Angeles in California showcases 30 active trials exploring interventions such as PF-06865571 and Obeticholic Acid. Additionally,Tucson in Arizona presents a promising hub with 29 studies focusing on treatments like MGL-3196 and Semaglutide (SEMA). Lastly, New york City contributes to the advancement of knowledge through its collection of 28 active trials targeting belapectin, PF-06865571,and Tirzepatide. These cities serve as crucial centers for cutting-edge research aimed at combatting fatty liver disease effectively.
Which are the top treatments for fatty liver disease being explored in clinical trials?
Clinical trials are shedding light on the most promising treatments for fatty liver disease. Semaglutide, a drug that made its debut in 2016, is currently being explored in four active trials and has been part of 11 clinical studies dedicated to this condition. Pioglitazone, first listed in 2002, is another contender with two ongoing trials and a total of 13 fatty liver disease studies under its belt. Lastly, EFX, introduced just last year in 2019, shows potential as it participates in two active trials among three all-time clinical investigations focused on combating fatty liver disease. These advancements offer hope for those suffering from this prevalent health issue.
What are the most recent clinical trials for fatty liver disease?
Recent clinical trials offer hope for individuals with fatty liver disease, paving the way for potential advancements in treatment. Of note are Part 1 Group 2 and LY3885125 (Part A), both Phase 1 trials that explore novel therapeutic approaches to combat this condition. Additionally, Reduction toward euinsulinemia (RE) protocol and BI 3006337 dose group 4 investigate new strategies to reduce insulin levels in patients with fatty liver disease. Another notable trial involves Diazoxide oral suspension at a specific dosage per weight, offering a fresh perspective on potential treatment options. These studies mark significant progress in our understanding of fatty liver disease and hold promise for improved patient outcomes moving forward.
What fatty liver disease clinical trials were recently completed?
Several clinical trials focusing on fatty liver disease have recently been concluded, reflecting the continuous efforts to combat this condition. Notably, Altimmune, Inc. completed two trials for ALT-801 in September 2021 and March 2022 respectively. In addition, BIO89-100 trial by 89bio, Inc., Efinopegdutide 20 mg/mL trial by Merck Sharp & Dohme Corp., AMG 609 trial by Amgen, TERN-201 trial by Terns, Inc., and ORMD-0801 (Insulin) capsule 8 mg BD trial sponsored by Oramed Ltd were all finished between August and November of either 2020 or 2021. These diverse studies signify the dedication of researchers across different organizations in their pursuit of effective treatments for fatty liver disease.